



NEW DATA & NEW TREATMENTS

CNS Activity of T-DXd in Pts with Active BM




TUXEDO-1 trial
Bartsch et al, Nat Med 2022

ORR-IC = 73% in pts with active BM



DEBBRAH trial
Perez-Garcia et al, Neuro Oncol 2022

ORR-IC = 46% in pts with active BM




DFCI/Duke/MDACCC series
Kabraji et al, Clin Ca Res 2022, in press

ORR-IC = 73%
(70% in pts with active BM)

DESTINY- Breast12

Study Design and Population



HER2 TKI + ADC Combinations

HER2CLIMB02: TDM1 +/- tucatinib

TBCRC 022: TDM1 + neratinib HER2CLIMB04:

TDXd + tucatinib

Phase 1b ZN1041 + HER2 therapies (TDM1, TDXd, HP)